NovaGo Therapeutics AG named finalist for prestigious Strüngmann Award 2025
30-05-2025 – Swiss Biotech Startups dominate the prestigious Strüngmann Award 2025 - NovaGo Therapeutics AG among the three finalists
Wyss Zurich startup NovaGo Therapeutics has been selected as one of three finalists for the 2025 Strüngmann Award, a high-profile prize honoring groundbreaking biotech entrepreneurs in the DACH region. The award, which includes a €100K prize, celebrates transformative scientific innovation paired with entrepreneurial vision and persistence.
NovaGo Therapeutics was co-founded by Prof. Martin E. Schwab, a globally renowned neuroscientist whose research has redefined the field of neuroregeneration. His discovery of Nogo-A, a key inhibitor of nerve repair in the central nervous system, laid the foundation for NovaGo’s mission: to translate decades of research into regenerative antibody therapies for spinal cord injuries and other neurological conditions.
Since its founding in 2015, NovaGo has made significant strides in developing therapeutic candidates aimed at restoring neural function. In 2023, Dr. Stefan Moese joined as CEO, bringing deep expertise in biologics development and translational medicine. Together, Schwab and Moese have positioned NovaGo as a leader in CNS repair — advancing promising therapeutics toward the clinic.
The recognition by the Strüngmann Award Committee underscores NovaGo's impactful progress at the intersection of science and entrepreneurship. As a Wyss Zurich project, this nomination reflects the strength of academic innovation translated into real-world therapeutic solutions with the potential to transform patients' lives.
The winner will be announced on July 3, 2025.
